A Phase I/II, Two-Staged, Single-Center, Randomized, Double-Blind, Antibody Titer Study to Assess Immunogenicity and Safety of FluMist Intranasal Influenza Vaccine Administered With and Without a TLR-3 Agonist, Ampligen
Phase of Trial: Phase I/II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Rintatolimod (Primary) ; Influenza virus vaccine live
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- Sponsors Hemispherx Biopharma
- 22 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 03 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 03 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.